FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120079423> ?p ?o ?g. }

• W3120079423 endingPage "103045" @default.
• W3120079423 startingPage "103045" @default.
• W3120079423 abstract "The Covid-19 disease has posed several challenges to the health care system across the world. This pandemic has affected nearly 220 countries as of date December 27, 2020 with an approximately 80 million people affected, 56 million recovered populations across the world and about 10 million affected and 9.7 million recovered cases in India [[1]Worldometer COVID-19 coronavirus pandemic.2020https://www.worldometers.info/coronavirus/#countriesGoogle Scholar]. With high rates of transmission of the disease and with no proven curative treatment available, health care systems across the world are severely overwhelmed. The covid-19 disease symptoms range from being asymptomatic, mild to moderate self-limiting respiratory tract illness to severe progressive pneumonia, multi-system involvement, multi-organ failure and death [[2]Joost Wiersinga W. Rhodes Andrew et al.Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) a review.JAMA. 2020; 324: 782-793https://doi.org/10.1001/jama.2020.12839Crossref PubMed Scopus (2826) Google Scholar]. For treatment purposes various therapeutic agents are being explored, in addition to the standard supportive care including oxygen supply, intensive care admission, or even extra-corporeal membrane oxygenation for critically ill patients [[3]Barbaro Ryan P. MacLaren Graeme et al.Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry.Lancet. 2020; 396: 1071-1078https://doi.org/10.1016/S0140-6736(20)32008-0Abstract Full Text Full Text PDF PubMed Scopus (541) Google Scholar]. Among therapeutic agents Antiviral Drugs, Antibacterials, Antimalarials, Monoclonal Antibodies, Corticosteroids are currently under evaluation for treatment of Covid-19 [[4]Pooladanda V. Thatikonda S. et al.The current understanding and potential therapeutic options to combat COVID-19.J Life Sci Elsevier. 2020; 254117765Crossref PubMed Scopus (60) Google Scholar]. Earliest studies of Seroprevalance of SARS-CoV-2 from various parts of the world was found to be: 2.7 % among blood donors by Gallian et al. [[5]GallianP. Pastorino B. Morel P. et al.Lower prevalence of antibodies neutralising SARS-CoV-2 in group O French blood donors.Antiviral Res. 2020; 181104880https://doi.org/10.1016/j.antiviral.2020.104880Crossref PubMed Scopus (87) Google Scholar] (March-april 2020); 5.0 % among household population by Pollan et al. [[6]Pollan M. Perez-Gomez B. et al.Prevalence of SARS-CoV-2 in spain (ENE-COVID): a nation-wide, population based sero-epidemiological study.Lancet. 2020; 396: 535-544Abstract Full Text Full Text PDF PubMed Scopus (1110) Google Scholar] (April-May 2020), 11 % among adult volunteers by Vena et al. [[7]Vena A. Berruti M. Adessi a Blumetti P. Brignole m et al.Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors.J Clin Med. 2020; 9E2780Crossref PubMed Scopus (53) Google Scholar]. (March-April2020), 22.7 % among adults in Blaine by McLaughlin et al. [[8]McLaughlin C.C. Doll M.K. Morrison K.T. et al.High community SARS-CoV-2-antibody prevalence in Ski-Resort Community, Blain Country, Idaho, US. Preliminary Results.MedRxiv. 2020; Google Scholar]. (May 2020), 31.5 % among asymptomatic residents by Naranbhai et al. [[9]Naranbhai V. Chang C.C. Beltran W.F.G. Miller T.E. et al.High seroprevalence of anti-SARS-VoV-2 antibodies in Chelsea, Massachusetts.J Infec Dis. 2020; PubMed Google Scholar]; 21–37 % among healthy blood donors by Younas et al. [[10]Younas A. Waheed S. Khawaja S. Imam M. et al.Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakisthan.Transfus Apher Sci. 2020; : 102Google Scholar]. (June-July). The various studies showed increase in seroprevalence among general population as the blood donors as the SARS-CoV-2-disease expanded into the population [[14]Lai Chih-Cheng Wang Jui-Hsiang Hsueh Po-Ren Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review.Int J Infect Dis. 2020; 101: 314-322https://doi.org/10.1016/j.ijid.2020.10.011Abstract Full Text Full Text PDF PubMed Scopus (125) Google Scholar]. Yet the seroprevalence seems underestimated with disease expanding into the population. With rise in the number of cases and symptomatic cases, the seroprevalence in the general population and so in the donor population shall increase with time. Plasma from patients who have recovered from Covid-19 infection namely Convalescent plasma (CP), is a treatment with considerate historical background in other diseases, but still explorative in context of Covid-19 [[11]Cunningham A.C. Goh H.P. Koh D. Treatment of Covid-19: old tricks for new challenges.Crit Care. 2020; 24: 91Crossref PubMed Scopus (192) Google Scholar]. Convalescent plasma therapy, a classic adaptive immunotherapy, which was successfully used over past two decades in treatment of SARS, Middle East Respiratory Syndrome (MERS) [[11]Cunningham A.C. Goh H.P. Koh D. Treatment of Covid-19: old tricks for new challenges.Crit Care. 2020; 24: 91Crossref PubMed Scopus (192) Google Scholar], H1N1(2009) with satisfactory efficacy and safety [[12]Arabi Yaseen M. Hajeer Ali H. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia.Emerg Infect Dis. 2016; 22: 1554-1561https://doi.org/10.3201/eid2209.151164Crossref PubMed Scopus (173) Google Scholar]. Since the virological and clinical characteristics share similarity among SARS, MERS and COVID-19, Convalescent Plasma therapy might be promising treatment for Covid-19 [[13]Wong S.S. Yuen K.Y. The management of coronavirus infections with particular reference to SARS.J Antimicrob Chemother. 2008; 62: 437-441Crossref PubMed Scopus (79) Google Scholar]. The convalescent plasma can be whole blood derived convalescent plasma or obtained by apheresis technique which utilises equipment: cell separator and disposable kits. Whole blood derived Convalescent plasma requires an addition of SARS-CoV-2 antibody test to the existing mandatory tests, with no additional sampling requirement except for the ones done at the time of whole blood donation. From the donor units containing SARS-CoV-2-IgG antibodies, FFP can be segregated into Convalescent plasma inventory and stored for use in convalescent plasma therapy. Also heterogeneous units of plasma from at least two donors can be transfused for a single patient, to achieve therapeutic benefit in terms of immune protection from delivery of diverse antibodies [[15]Epstein Jay Burnouf Thierry Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma.Vox Sanguis. 2020; 115https://doi.org/10.1111/vox.12939Crossref Scopus (55) Google Scholar]. Considering whole blood derived Convalescent plasma shall be an economical option for Convalescent Plasma Therapy in low and middle income countries where basic infrastructure for performing apheresis procedures are not available. Apheresis derived products are expensive, require technical expertise and recipient blood group matched donor. In view of ongoing pandemic, additional efforts by the Blood centres are needed to motivate apheresis donations, where the CP donors carry the fear of losing protective antibodies post donation. Now that the whole blood donations have stabilised Further, In similar lines of fractionation of plasma derived products like – immunoglobulins, albumin, factor V, VII, VIII concentrates, SARS-CoV-2 antibodies can also be extracted, lyophilized [[16]Joesph Fernandez M. Maisha Nuzhat Lavik Erin B. Cannon Jeremy W. The chemistry of lyophilized blood products.Bioconjug Chem. 2018; 29: 2150-2160https://doi.org/10.1021/acs.bioconjchem.8b00271Crossref PubMed Scopus (9) Google Scholar] and utilised as a plasma product with longer storage periods and ease of handling, which can even be supplied to remove areas with ease. With the second wave of Covid-19 and upcoming third wave along with other modalities of treatment, preparedness in terms of CP can be achieved by segregating Whole Blood derived FFP/plasma units with adequate SARS-CoV-2-antibody levels with addition of SARS-CoV-2 antibody test to the whole blood donations along with mandatory tests as per the country’s regulations. Also, low prevalence blood group CP stock can be maintained. Whole blood derived Covid-Convalescent plasma is the best economical alternative option in low and middle income countries. Also reserves of Covid-convalescent plasma can be maintained with addition of SARS-CoV-2 antibody test to the whole blood donations unlike the Apheresis derived Convalescent plasma, which requires additional consumables like Cell separator machines, disposable kits, thereby limiting the bulk stock storage." @default.
• W3120079423 created "2021-01-18" @default.
• W3120079423 creator A5026030675 @default.
• W3120079423 creator A5034861642 @default.
• W3120079423 creator A5062111581 @default.
• W3120079423 date "2021-04-01" @default.
• W3120079423 modified "2023-09-26" @default.
• W3120079423 title "Whole blood derived covid convalescent plasma: An economical option among developing countries" @default.
• W3120079423 cites W2152233129 @default.
• W3120079423 cites W2460100043 @default.
• W3120079423 cites W2803119431 @default.
• W3120079423 cites W3012546754 @default.
• W3120079423 cites W3017045802 @default.
• W3120079423 cites W3022872787 @default.
• W3120079423 cites W3040552450 @default.
• W3120079423 cites W3041319886 @default.
• W3120079423 cites W3043138331 @default.
• W3120079423 cites W3080372176 @default.
• W3120079423 cites W3081511160 @default.
• W3120079423 cites W3084121155 @default.
• W3120079423 cites W3089328061 @default.
• W3120079423 cites W3092342242 @default.
• W3120079423 doi "https://doi.org/10.1016/j.transci.2020.103045" @default.
• W3120079423 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7776123" @default.
• W3120079423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33419658" @default.
• W3120079423 hasPublicationYear "2021" @default.
• W3120079423 type Work @default.
• W3120079423 sameAs 3120079423 @default.
• W3120079423 citedByCount "5" @default.
• W3120079423 countsByYear W31200794232021 @default.
• W3120079423 countsByYear W31200794232022 @default.
• W3120079423 crossrefType "journal-article" @default.
• W3120079423 hasAuthorship W3120079423A5026030675 @default.
• W3120079423 hasAuthorship W3120079423A5034861642 @default.
• W3120079423 hasAuthorship W3120079423A5062111581 @default.
• W3120079423 hasBestOaLocation W31200794231 @default.
• W3120079423 hasConcept C116675565 @default.
• W3120079423 hasConcept C126322002 @default.
• W3120079423 hasConcept C159047783 @default.
• W3120079423 hasConcept C177713679 @default.
• W3120079423 hasConcept C2779134260 @default.
• W3120079423 hasConcept C3006700255 @default.
• W3120079423 hasConcept C3007834351 @default.
• W3120079423 hasConcept C3008058167 @default.
• W3120079423 hasConcept C3018027319 @default.
• W3120079423 hasConcept C524204448 @default.
• W3120079423 hasConcept C71924100 @default.
• W3120079423 hasConceptScore W3120079423C116675565 @default.
• W3120079423 hasConceptScore W3120079423C126322002 @default.
• W3120079423 hasConceptScore W3120079423C159047783 @default.
• W3120079423 hasConceptScore W3120079423C177713679 @default.
• W3120079423 hasConceptScore W3120079423C2779134260 @default.
• W3120079423 hasConceptScore W3120079423C3006700255 @default.
• W3120079423 hasConceptScore W3120079423C3007834351 @default.
• W3120079423 hasConceptScore W3120079423C3008058167 @default.
• W3120079423 hasConceptScore W3120079423C3018027319 @default.
• W3120079423 hasConceptScore W3120079423C524204448 @default.
• W3120079423 hasConceptScore W3120079423C71924100 @default.
• W3120079423 hasIssue "2" @default.
• W3120079423 hasLocation W31200794231 @default.
• W3120079423 hasLocation W31200794232 @default.
• W3120079423 hasLocation W31200794233 @default.
• W3120079423 hasLocation W31200794234 @default.
• W3120079423 hasOpenAccess W3120079423 @default.
• W3120079423 hasPrimaryLocation W31200794231 @default.
• W3120079423 hasRelatedWork W3047760116 @default.
• W3120079423 hasRelatedWork W3082210356 @default.
• W3120079423 hasRelatedWork W3094105805 @default.
• W3120079423 hasRelatedWork W3127693599 @default.
• W3120079423 hasRelatedWork W4210401150 @default.
• W3120079423 hasRelatedWork W4214661089 @default.
• W3120079423 hasRelatedWork W4283747128 @default.
• W3120079423 hasRelatedWork W4321179355 @default.
• W3120079423 hasRelatedWork W3087165796 @default.
• W3120079423 hasRelatedWork W3202143347 @default.
• W3120079423 hasVolume "60" @default.
• W3120079423 isParatext "false" @default.
• W3120079423 isRetracted "false" @default.
• W3120079423 magId "3120079423" @default.
• W3120079423 workType "article" @default.